Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search span> per sponsor: Orion Corporation Orion Pharma
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
Effects of ODM-109 on respiratory function in patients with ALS
The primary objective of the study is to investigate the efficacy of oral levosimendan on respiratory function in patients with Amyotrophic Lateral Sclerosis.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
EFFECTS OF ORAL LEVOSIMENDAN ON AMBULATORY ELECTROCARDIOGRAPHIC VARIABLES AND CEREBROVASCULAR REACTIVITY IN PATIENTS WITH RECENT STROKE OR TIA. A RANDOMISED, DOUBLE BLIND, PLACEBO-CONTROLLED, DOSE FINDING, MULTICENTRE STUDY WITH PARALLEL GROUP DESIGN
The primary objective is to explore the safety of low doses of oral levosimendan in patients with recent history of an ischaemic cerebrovascular event (stroke or TIA). The main focus will be on the ev...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
A study of ORM-12741 on cognitive and behavioural symptoms such e.g. memory, orientation, learning in patients with Alzheimer’s disease (form of dementia)
The primary objectives of the study are to evaluate the safety and tolerability of ORM-12741, and the efficacy of ORM-12741 on cognitive symptoms in patients with Alzheimer’s disease (AD) receiving ac...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
Comparison of effectiveness of two different kinds of inhalers on bronchodilation in people with asthma
The objective of the study is to confirm equivalent bronchodilator efficacy of the test product (Budesonide/formoterol Easyhaler) compared to the reference product (Symbicort Turbuhaler).
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
SAFETY, ABSORPTION AND DISTRIBUTION OF ODM-201 IN PATIENTS WITH PROSTATE CANCER:
To evaluate safety and tolerability of ODM-201 and to define dose(s) of ODM-201 for further clinical studies. Dose-limiting toxicities (DLT) and the MTD and/or OTD will be determined.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
Confronto degli effetti di due sedativi, la dexmedetomidina e il propofol, in pazienti che hanno bisogno di ricominciare a respirare senza un macchinario e che hanno difficolta' a farlo. A comparison of the effects of two calming drugs, dexmedetomidine and propofol, in patients who need to start breathing without the help of a machine and are having difficulty doing so
The primary objective is to investigate effects of dexmedetomidine on diaphragmatic neural activity (EAdi) over 24 hours after starting study treatment in difficult to wean mechanically ventilated p...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
A study of ORM-12741 for the prevention of blood vessel spasm brought on by cold temperature
To evaluate the efficacy of ORM-12741 in the attenuation of a cold-induced reduction in finger blood flow and temperature in subjects with Raynaud's Phenomenon (RP) secondary to systemic sclerosis in...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH PROPOFOL FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT
The study has hierarchical co-primary objectives to demonstrate that: • Firstly: dexmedetomidine is at least as effective as sedation with propofol and daily sedation stops, in maintaining a target de...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
A PROSPECTIVE, MULTI-CENTRE, RANDOMISED, DOUBLE-BLIND COMPARISON OF INTRAVENOUS DEXMEDETOMIDINE WITH MIDAZOLAM FOR CONTINUOUS SEDATION OF VENTILATED PATIENTS IN INTENSIVE CARE UNIT
The study has hierarchical co-primary objectives to demonstrate that: • Firstly: dexmedetomidine is at least as effective as sedation with midazolam and daily sedation stops, in maintaining a target d...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 5 ans
Safety and pharmacokinetics of ODM-204 in patients with metastatic castration -resistant prostate cancer: an open-label, non - randomised, uncontrolled, multicentre, dose escalation, first-in- man study with additional expansion phase with a dose selected in the escalation phase Ensimmäisen vaiheen turvallisuus- ja imeytymistutkimus ODM-204 valmisteella kastraatiohoitoon reagoimattomilla eturauhassyöpäpotilailla: avoin, satunnaistamaton, kontrolloimaton, nousujohteiseen annoksen nostoon perustuva monikeskus- ja annoslaajennustutkimus
To evaluate safety and tolerability of ODM-204 including dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD), if possible
Country
None
organs
None
Specialty
None
unknown
More information
1
2
Next